Navigation Links
Sorrento Announces the Unexpected Death of its Chief Business Officer
Date:7/31/2014

SAN DIEGO, July 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.

"Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Amar's family and friends," said Henry Ji, Ph.D., Sorrento's President and Chief Executive Officer.

Mr. Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where he served as SVP and Chief Business Officer since December 2010. Previously, Mr. Singh served as: Chief Operating Officer of Spectrum Pharmaceuticals, where he led the commercial and business development teams; VP and Chief Commercial Officer at Novacea responsible for securing partnerships; and Chief Commercial Officer at Abraxis where he led the launch of Abraxane®. Prior to Abraxis, Mr. Singh held multiple commercial leadership positions in the oncology franchise at Hoffman-La Roche for over 10 years. Mr. Singh holds an M.B.A. from the Stern School of Business at New York University and a B.A. from the University of North Carolina at Chapel Hill.

About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bispecific therapeutic antibodies, and ADCs.

More information is available at www.sorrentotherapeutics.com.


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor
2. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
3. Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
4. Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
5. Sorrento Therapeutics Adopts Stockholder Rights Plan
6. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
7. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
8. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
9. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
10. Sorrento Therapeutics Completes IgDraSol Merger
11. Sorrento Therapeutics to Present at Two Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Stryker announced today that it has ... in partnership with Great Place to Work (GPTW). We ... This list highlights the top U.S. companies with 1,000 ... also demonstrating respect, compassion and concern for their employees, ... determine the companies on the list, GPTW asked more ...
(Date:3/29/2017)... 2017 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a ... the year ended December 31, 2016 after market ... are being released later than the previous fiscal ... the operations and balances of Apicore from the ... and filing date meets TSX Venture Exchange listed ...
(Date:3/28/2017)... Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023" Report ... the Chemotherapy Induced Neutropenia for the seven major markets i.e., ... France , Germany , ... Japan , as well as rest of ... The Report covers the therapeutics market revenue, treatment practice and ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with wearing oral braces. "The rubber bands used in conjunction with my braces ... I decided to design a way to prevent this problem." The O.B.S. was ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location dental office in ... treatments. Dental lasers are safe and effective options, and can be used alone or ... the overall quality of care. , Dr. Hamid Reza of Hamlin Dental Group offers ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is ... Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating ... Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, ...
(Date:3/28/2017)... ... ... women, getting birth control isn’t as easy as it should be. In fact, millions of ... health care facility or a pharmacy within 60 minutes of where they live. This is ... who are faced with health or personal issues that leave them homebound. To help facilitate ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... representatives in state legislatures and Congress to protect parental rights and civil liberties, ... and safety in America. , The demonstration coincides with a press conference taking ...
Breaking Medicine News(10 mins):